Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 3Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genital Diseases 1Colonic Neoplasms 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2sintilimab 1serabelisib 1sapanisertib 1rucaparib 1pembrolizumab 1palbociclib 1olaparib 1durvalumab 1ceralasertib 1adavosertib 1Therapeutics 1Restraint, Physical 1Radiation, Ionizing 1Radiation 1Platinum 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Fulvestrant 1Congresses as Topic 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Endometrioid × serabelisib × Gynecologic × Clear all
NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Faeth Therapeutics

Phase 2 Recruiting
40 enrolled
Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡